Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
European Cytokine Network|June 28, 2007
Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cellsEvemie Schutyser, Yingjun Su, Yingchun Yu, et al.
ACS Applied Materials & Interfaces|October 12, 2022
Multifunctional Histidine Cross-Linked Interface toward Efficient Planar Perovskite Solar CellsYan Li, Siqi Li, Yujie Shen, et al.
Polymers|May 5, 2019
Synthesis and Characterization of Graphene Oxide/Chitosan Composite Aerogels with High Mechanical PerformanceYang Gong, Yingchun Yu, Huixuan Kang, et al.
Journal of Separation Science|April 15, 2021
Purification of linarin and hesperidin from Mentha haplocalyx by aqueous two-phase flotation coupled with preparative HPLC and evaluation of the neuroprotective effect of linarinJiajia Zeng, Weilun Hu, Hao Li, et al.
Dalton Transactions (Cambridge, England : 2003)|August 15, 2018
One step fabrication of novel Ag-CdS@EP floating photocatalyst for efficient degradation of organic pollutants under visible light illuminationUsman Ali Khan, Jianjun Liu, Jinbo Pan, et al.
Plos One|May 3, 2014
Activation of MAPK and FoxO by manganese (Mn) in rat neonatal primary astrocyte culturesVernat Exil, Li Ping, Yingchun Yu, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|September 19, 2012
Chlorpyrifos-, diisopropylphosphorofluoridate-, and parathion-induced behavioral and oxidative stress effects: are they mediated by analogous mechanisms of action?Caridad López-Granero, Fernando Cañadas, Diana Cardona, et al.
Journal of Leukocyte Biology|May 29, 2008
Short tail with skin lesion phenotype occurs in transgenic mice with keratin-14 promoter-directed expression of mutant CXCR2Yingchun Yu, Yingjun Su, Susan R Opalenik, et al.
Journal of Colloid and Interface Science|August 14, 2022
High Sulfur-doped hollow carbon sphere with multicavity for high-performance Potassium-ion hybrid capacitorsLantao Liu, Yiming Li, Shuaize Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targetsYingjun Su, Katayoun I Amiri, Linda W Horton, et al.
Pageof 5